Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Carbone

Showing results (211-220 of 283) with videos related to

Pageof 29
Sort By:
JAMA Oncology|July 25, 2024
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled TrialHelen J Ross, David Kozono, Xiaofei F Wang, et al.
Oncoimmunology|February 21, 2025
Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patientsAnet Greib, Songzhu Zhao, Michelle Ploch, et al.
Nature Communications|July 31, 2021
AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicingGeorgios I Laliotis, Evangelia Chavdoula, Maria D Paraskevopoulou, et al.
British Journal of Cancer|October 17, 2022
Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodulesXinyu Zhang, Zhuo Yu, Yaping Xu, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
An <i>in vivo</i> "turning model" reveals new RanBP9 interactions in lung macrophagesYasuko Kajimura, Anna Tessari, Arturo Orlacchio, et al.
Nature Communications|June 28, 2022
Retraction Note: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicingGeorgios I Laliotis, Evangelia Chavdoula, Maria D Paraskevopoulou, et al.
Journal of Geriatric Oncology|February 25, 2021
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancerAndrew C Johns, Lai Wei, Madison Grogan, et al.
Science Translational Medicine|January 28, 2026
SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibitionYaogang Zhong, Feng Geng, Huali Su, et al.
Molecular & Cellular Proteomics : MCP|July 5, 2012
In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkersTakefumi Kikuchi, Mohamed Hassanein, Joseph M Amann, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapyAdam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.
Pageof 29

Showing results (211-220 of 283) with videos related to

Sort By:
Pageof 29
JAMA Oncology|July 25, 2024
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled TrialHelen J Ross, David Kozono, Xiaofei F Wang, et al.
Oncoimmunology|February 21, 2025
Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patientsAnet Greib, Songzhu Zhao, Michelle Ploch, et al.
Nature Communications|July 31, 2021
AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicingGeorgios I Laliotis, Evangelia Chavdoula, Maria D Paraskevopoulou, et al.
British Journal of Cancer|October 17, 2022
Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodulesXinyu Zhang, Zhuo Yu, Yaping Xu, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
An <i>in vivo</i> "turning model" reveals new RanBP9 interactions in lung macrophagesYasuko Kajimura, Anna Tessari, Arturo Orlacchio, et al.
Nature Communications|June 28, 2022
Retraction Note: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicingGeorgios I Laliotis, Evangelia Chavdoula, Maria D Paraskevopoulou, et al.
Journal of Geriatric Oncology|February 25, 2021
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancerAndrew C Johns, Lai Wei, Madison Grogan, et al.
Science Translational Medicine|January 28, 2026
SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibitionYaogang Zhong, Feng Geng, Huali Su, et al.
Molecular & Cellular Proteomics : MCP|July 5, 2012
In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkersTakefumi Kikuchi, Mohamed Hassanein, Joseph M Amann, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapyAdam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.
Pageof 29